Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 305

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 305
---
of assays based on the analysis of cell-free brain/other organ-enriched miRNAs detectable in blood plasma to facilitate better understanding
of RTT-associated pathophysiological processes and development of therapeutics for RTT. (PLoS One, 2019; doi: 10.1371/journal.pone.0218623;
Rett Syndrome Foundation Research Trust Conference, 2023, Boston MA, poster presentation)

<div align='center'>173</div>

On June 19, 2024, DiamiR made
an oral presentation at the 2024 Rett Syndrome Scientific Meeting titled “Circulating Organ-enriched microRNAs as Biomarkers of
Rett Syndrome” (https://www.prnewswire.com/news-releases/DiamiR-announces-oral-presentation-on-recent-advances-of-its-microrna-biomarker-platform-at-2024-international-rett-syndrome-foundation-scientific-meeting-302170263.html?tc= eml_cleartime). On behalf of DiamiR, Dr. Sheinerman presented findings from a Rett microRNA biomarker study conducted
between 2021 and 2024. Levels of 44 microRNAs were analyzed in plasma samples of 163 study participants, including 81 Rett syndrome patients
and 82 age-matched individuals without Rett syndrome, of three age groups: younger than 5 years old, 5 to 15 years old, and
older than 16 years old. The blood samples for the study were provided by the Tri-State Rett Syndrome Center, Montefiore Medical
Center. In line with DiamiR’s previously described results (see Business section, Circulating Organ-enriched miRNAs as Biomarkers
of Rett Syndrome), the microRNA panel effectively differentiated study participants with Rett syndrome.

To develop a marketable RTT
diagnostic solution, DiamiR plans to offer both sequencing services (of the MECP2 gene) and its proprietary miRNA panel. DiamiR
is currently evaluating 3 party vendors to develop a custom NGS assay for Rett syndrome on a MiSeQ platform (Illumina).

BEYOND BRAIN HEALTH: UNIVERSAL SCREENING TEST

DiamiR believes its core miRNA
technology is robust and applicable to early detection of disease pathology in different organs, not only in the brain, which enables
a novel approach to screening whereby a battery